Abstract
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T‐cell therapy in a subset of B‐cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene‐modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.
Funding Information
  • National Health and Medical Research Council (APP1062580, APP1132373)
  • Cancer Council Victoria (APP1143517)
  • National Breast Cancer Foundation (ECF‐17‐005)
  • National Health and Medical Research Council (APP1136680)

This publication has 139 references indexed in Scilit: